Methotrexate - The anchor drug - An introduction

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 61, 2010, Pages

  Pincus, T ^a   Cronstein, B ^b   Braun, J ^c  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c St Josefs Krankenhaus   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE;

BLOOD CELL COUNT; DISEASE COURSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG INFORMATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG USE; EDITORIAL; HUMAN; LONG TERM CARE; LOW DRUG DOSE; PATIENT CARE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; ARTICLE; DRUG BIOAVAILABILITY; DRUG SAFETY; HEALTH PRACTITIONER; PRACTICE GUIDELINE; PRESCRIPTION; RISK FACTOR; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; METHOTREXATE; RHEUMATIC DISEASES; TREATMENT OUTCOME;

EID: 78650581157     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Editorial

References (11)

1. PINCUS T, YAZICI Y, SOKKA T, ALETAHA D, SMOLEN JS: Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003;21(Suppl. 31): S179-S185.
2. VISSER K, KATCHAMART W, LOZA E et al.: Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086-93.
3. SOKKA T, KAUTIAINEN H, TOLOZA S et al.: QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 2007;66:1491-6. (Pubitemid 350032658)
4. PINCUS T, YAZICI Y, BERGMAN MJ: Hotel-based medicine. J Rheumatol 2008;35:1487-8.
5. DONAHUE KE, GARTLEHNER G, JONAS DE et al.: Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008;148:124-34.
6. YAZICI Y, SOKKA T, KAUTIAINEN H, SWEARINGEN C, KULMAN I, PINCUS T: Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005;64:207-11.
7. PINCUS T, FERRACCIOLI G, SOKKA T et al.: Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology 2002;41:1346-56.
8. LANDEWÉ R, VAN DER HEIJDE D: Radiographic progression in rheumatoid arthritis. Clin Exp Rheumatol 2005;23(Suppl. 39): S63-68.
9. CHAN E S L, CRONSTEIN BN: Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002;4:266-73.
10. PINCUS T, HUIZINGA T W J, YAZICI Y: N-of-1 trial of low-dose methotrexate and/or prednisolone in lieu of anti-CCP, MRI, or ultrasound, as first option in suspected rheumatoid arthritis? J Rheumatol 2007;34:250-2.
11. HOFFMEISTER RT: Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med 1983;75(Suppl. 6 A): S69-73.